Business Update Neutral

2026-05-27 16:13

Mankind Pharma Limited announced that its management will participate in an Investor Conference organized by Bank of America on June 1, 2026, and hold meetings with various investors on June 2, 2026, in Mumbai. The company confirmed that no unpublished price sensitive information will be disclosed during these interactions, with discussions based on general business outlook and publicly available information.

Business Update Positive

2026-05-26 17:03

Management guided for FY27 to be a much better year with double-digit top-line growth, aiming to outperform IQVIA, driven by normalization in acute portfolio, sustained chronic therapy momentum, and increasing specialty/differentiated products including a recently launched GLP-1 pen. EBITDA margin is expected to be 25.5-26.5% for FY27 (vs 25.4% in FY26). International business is projected for high double-digit growth, reaching high teens to 20%. Capex for FY27 is guided at 6-7% of revenue, including a new biotech facility. The company is on track to repay acquisition-related debt by FY28, with the net debt to adjusted EBITDA ratio expected to reach 0.5x in FY27. The effective tax rate for FY27 is projected to increase to 25-26% due to the end of Sikkim exemption.

Business Update Neutral

2026-05-20 21:13

Mankind Pharma Limited announced that its management and officials will participate in investor meetings in Singapore on May 25-26, 2026. The discussions will be based on the general business outlook and information already in the public domain, with no unpublished price sensitive information being disclosed. The schedule for the investor conference is subject to change.

Business Update Neutral

2026-05-20 16:04

Mankind Pharma Limited informed about the availability of the audio recording for its Investor Conference Call for Q4 & FY26, which was held on May 20, 2026. The recording can be accessed on the company's website at https://www.mankindpharma.com/MankindPharma-Earnings-May20-2026.mp4.

Financials Positive

2026-05-19 20:11

Consolidated Revenue ₹3,443Cr vs ₹3,079Cr (▲11.8% YoY), Adjusted EBITDA ₹933Cr vs ₹711Cr (▲31.1% YoY), PAT ₹559Cr vs ₹429Cr (▲30.4% YoY). Adjusted EBITDA Margin 27.1% vs 23.1% (▲400bps).

Ownership Neutral

2026-05-19 19:29

Mankind Pharma Limited, on May 19, 2026, allotted 80,872 equity shares of ₹1/- face value to eligible employees under its ESOP Plan 2022. This increases the company's paid-up share capital from 41,28,28,328 to 41,29,09,200 Equity Shares. The shares rank pari-passu with existing shares. Exercise prices for these allotted shares range from ₹860.00 to ₹1,600.00 per share.

Financials Positive

2026-05-19 19:23

CRITICAL RED FLAG DETECTED

Mankind Pharma reported strong standalone financial results for Q4 FY26 with Revenue ₹2,581.82 Cr vs ₹2,119.46 Cr (▲21.89% YoY), EBITDA ₹896.02 Cr vs ₹341.84 Cr (▲162.15% YoY), and PAT ₹713.61 Cr vs ₹235.16 Cr (▲203.46% YoY). EBITDA Margin expanded significantly from 16% to 35% (▲1900bps). The Board also approved an additional investment of up to ₹500 crores in a wholly-owned subsidiary and noted that Executive Directors will not draw commission for FY2025-26 to strengthen cash for business expansion. However, the resignation of Mr. Pramod Gokhale, Global Chief Information Officer (KMP), was also noted.

Financials Negative

2026-05-19 19:20

CRITICAL RED FLAG DETECTED

Standalone Revenue ₹2,581.82 Cr vs ₹2,119.46 Cr (▲21.81% YoY), EBITDA ₹1,022.72 Cr vs ₹561.35 Cr (▲82.19% YoY), PAT ₹713.61 Cr vs ₹235.16 Cr (▲203.46% YoY). EBITDA Margin 39.61% vs 26.49% (▲1312 bps).

Financials Positive

2026-05-19 19:20

CRITICAL RED FLAG DETECTED

Mankind Pharma reported strong standalone Q4 FY26 results with Operating Revenue at ₹2,581.82 Cr vs ₹2,119.46 Cr (▲21.82% YoY), EBITDA at ₹896.02 Cr vs ₹341.84 Cr (▲162.1% YoY), and PAT at ₹713.61 Cr vs ₹235.16 Cr (▲203.46% YoY). EBITDA Margin expanded by 1857 bps to 34.70% from 16.13%. The board also approved an additional investment of up to ₹500 crores in a wholly-owned subsidiary and noted key executive directors foregoing commission for FY26 to strengthen cash. However, Mr. Pramod Gokhale (Global CIO) resigned, and auditors highlighted ongoing income tax proceedings regarding ₹1,868.89 crores in adjustments for previous years.

Financials Neutral

2026-05-19 19:16

CRITICAL RED FLAG DETECTED

Standalone Revenue ₹2,581.82 Cr vs ₹2,119.46 Cr (▲21.89% YoY), EBITDA ₹903.64 Cr vs ₹339.11 Cr (▲166.47% YoY), PAT ₹713.61 Cr vs ₹235.16 Cr (▲203.46% YoY). EBITDA Margin 35% vs 16% (▲1900 bps). The company also approved the re-appointment of a Whole-Time Director and Cost Auditors, realignment of NCD security cover post ₹1,250 Cr redemption, and an additional investment of up to ₹500 Cr in a subsidiary. Executive Directors will not draw commission for FY26 to strengthen cash position.

Financials Positive

2026-05-19 19:16

CRITICAL RED FLAG DETECTED

Mankind Pharma Limited reported strong Q4 FY26 consolidated financial results. Consolidated Revenue from operations stood at ₹3,442.93 Cr vs ₹3,079.37 Cr (▲11.79% YoY), EBITDA was ₹909.71 Cr vs ₹685.51 Cr (▲32.70% YoY), and PAT (attributable to equity holders of parent) was ₹554.35 Cr vs ₹425.11 Cr (▲30.40% YoY). EBITDA Margin expanded to 26.42% vs 22.26% (▲416 bps). The Board also approved the realignment of security cover for NCDs post redemption of ₹1,250 Cr, additional investment of ₹500 Cr in a subsidiary, and the re-appointment of a Whole-Time Director and Cost Auditors. Executive Directors decided not to draw commission for FY26 to strengthen cash for business expansion.

Routine Positive

2026-05-12 18:46

Mankind Pharma Limited announced that ICRA Limited reaffirmed credit ratings for its Long-term/Short term fund based limits (₹1,250 crore) at [ICRA]AA+ (Stable)/[ICRA]A1+ and Non-convertible Debentures (₹5,000 crore) at [ICRA]AA+ (Stable). Additionally, a new rating of [ICRA]A1+ was assigned to its Commercial Paper (₹600 crore).

Business Update Neutral

2026-05-08 19:29

Mankind Pharma Limited announced an Investor Conference Call on May 20, 2026, at 12:00 PM IST, to discuss the company's Q4FY26 and full-year FY26 business performance and results. Senior management, including the Vice Chairman & Managing Director and CEO, will participate in the call.

Routine Neutral

2026-04-22 20:47

New Filing detected. See link for details.

Business Update Neutral

2026-04-13 15:29

The Board approved the closure/winding-up of Mankind Pharma Lanka (Private) Limited, a wholly-owned subsidiary in Sri Lanka, due to changed regulatory requirements making business objectives unviable. The subsidiary had no business operations and is not considered material.

Business Update Neutral

2026-04-13 15:26

Mankind Pharma's Board approved the closure/winding-up of its wholly-owned subsidiary, Mankind Pharma Lanka (Private) Limited in Sri Lanka, due to changed regulatory requirements making business objectives unviable. The subsidiary had no business operations and is not a material subsidiary.

Routine Neutral

2026-04-06 15:19

Mankind Pharma Limited submitted a certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, confirming no requests for dematerialisation/rematerialisation of shares were received for the quarter ended March 31, 2026.

Business Update Positive

2026-03-18 10:02

Mankind Pharma announced on March 18, 2026, the acquisition of the Rivotril brand from Roche for India. This strategic move strengthens the company's focus on chronic Central Nervous System (CNS) therapies and expands its neuro portfolio.

Ownership Positive

2026-03-16 13:45

Mankind Pharma Limited on March 16, 2026, allotted 23,256 equity shares under its ESOP Plan 2022 at an exercise price of ₹860 per share. This increased the paid-up share capital from 41,28,05,072 to 41,28,28,328 equity shares.

Business Update Positive

2026-02-26 18:27

Mankind Pharma announced that an appeal against an earlier order resulted in the dropping of a penalty of INR 1,02,05,688/- (approximately ₹1.02 Crore) under the CGST Act, 2017, for the financial years 2017-21.

Business Update Positive

2026-02-24 18:22

ICRA Limited has reaffirmed the Credit Ratings for Mankind Pharma Limited's Non-Convertible Debentures at (ICRA) AA+/Stable and Long-term/Short-term fund-based limits at (ICRA)AA+(Stable)/(ICRA)A1+ on February 24, 2026.

Business Update Neutral

2026-02-18 15:07

Mankind Pharma Limited will participate in the 'Chasing Growth 2026' Investor Conference in Mumbai on February 24, 2026. The meeting will involve one-on-one and group discussions. No unpublished price sensitive information will be shared at the conference.

Business Update Positive

2026-02-16 18:51

Mankind Pharma announced that the Joint Commissioner of State Tax, Nagpur, has issued an order dated February 16, 2026, dropping the penalty of INR 46,32,582/- related to a GST matter for FY2020-21, following the company's appeal against a previous order.

Business Update Negative

2026-02-09 15:04

CRITICAL RED FLAG DETECTED

Mankind Pharma disclosed a GST Department search/inspection at its unlisted subsidiary, Bharat Serums and Vaccines Limited, from February 3-8, 2026, relating to tax payments and input tax credit. The company stated operations continued as usual with no material impact.

Financials Positive

2026-02-09 13:42

Overall Revenue was INR 3,567 crores in Q3 FY26 compared to INR 3,199 crores in Q3 FY25, marking an 11.5% YoY increase. The adjusted EBITDA margin for Q3 FY26 was 25.9%.

Business Update Neutral

2026-02-04 13:56

Mankind Pharma Limited will participate in the MANTHAN – Systematix India Annual Flagship Conference on February 9, 2026, and the Advantage India - Axis Capital's Flagship India Conference on February 10, 2026, both in Mumbai. These will involve one-on-one and group meetings, with no unpublished price sensitive information being shared.

Routine Neutral

2026-02-03 22:04

New Filing detected. See link for details.

Financials Neutral

2026-02-03 16:31

CRITICAL RED FLAG DETECTED

Mankind Pharma's Board approved unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2025. The auditor's review report includes an emphasis of matter regarding pending income tax proceedings from an earlier year.

Financials Positive

2026-02-03 16:28

Consolidated Revenue ₹3,567Cr vs ₹3,199Cr (▲11.5% YoY), EBITDA ₹816Cr vs ₹819Cr (▼0.4% YoY). EBITDA Margin 22.9% vs 25.6% (▼270bps).

Financials Positive

2026-02-03 16:23

Consolidated Revenue ₹3,567Cr vs ₹3,199Cr (▲11.5% YoY), Adjusted EBITDA ₹923Cr vs ₹883Cr (▲4.6% YoY), PAT ₹414Cr vs ₹378Cr (▲9.5% YoY). Adjusted EBITDA Margin 25.9% vs 27.6% (▼170bps).

Financials Negative

2026-02-03 16:16

CRITICAL RED FLAG DETECTED

Mankind Pharma's Board approved standalone and consolidated financial results for the quarter ended December 31, 2025. A red flag is noted due to ongoing income tax proceedings, with disallowances totaling ₹1,825.66 Cr. The company has appealed these adjustments, stating no material impact on financials is expected.

MANKIND

Mankind Pharma Limited

Filing History

Unlock Full History